英文【EFPIA】患者W.A.I.T.指标2025

© 2025. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Published May 2025EFPIA Patients W.A.I.T. Indicator 2024 SurveyMax Newton, Principal, Strategic Partners (GS&AR) Kelsey Stoddart, Sr Consultant, Global Supplier & Association RelationsMarco Travaglio, Consultant, Global Supplier & Association RelationsPer Troein, VP, Strategic Partners1Indicators measure availability, restrictions to availability and time to availabilityForewordThe Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator has been running in evolving formats since 2004 and has offered a comprehensive overview of public reimbursement across over 30 countries since 2018.However, the relevance of whether an innovative molecule is included on public reimbursement lists has diminished over the years, with a rise in patient access through alternative channels and/or with restrictions. This year’s iteration of the report retains the core availability metrics, whilst adding additional context around the positioning of the report within the broader access landscape, and greater granularity on the level of restrictions to patient access (i.e. individual patient only). These updates aim to ensure the report remains relevant in new access landscape and support the accurate use of the W.A.I.T. report.Information on the availability of 173 innovative medicines with central-marketing authorisation between 2020 and 2023 are included in the report. There is a one-year delay to permit countries to include these medicines on their public reimbursement list, meaning that the data on availability is accurate as of January 5th 2025.Local pharmaceutical industry associations provide the information directly to IQVIA and EFPIA, and their definitions are included within the appendix to ensure full transparency. Long-runningThe Patients W.A.I.T. Indicator study has been running in evolving formats since 2004Broad coverageThe Patients W.A.I.T. dataset covers 26 countries and 4 years of novel medicine approvals, with a historic dataset covering 10-years of dataWidely referencedThe Patients W.A.I.T. report is used by all stakeholders to inform regional and national discussions on patient access2+ Background+ The Patients W.A.I.T. indicators1.Overview (all products) 2.Oncology 3.Orphan medicines4.Non-oncology orphan medicines 5.Combination therapies 6.Historic comparisons and extended period+ Methodology and definitionsContents3Patients W.A.I.T. Indicator 2024 Survey: Overview and updatesData not available / included Data availableEuropean countriesyear cohort (‘20-’23)364innovative medicines173Updates in 2024Additional contextTo clarify the scope of the W.A.I.T .Indicator report in providing data and insights on the access landscape in EuropeNew indicatorsTo provide granularity on when individual patient schemes are the only access routeReading guideTo support stakeholders in understanding the value, li